Skip to main content

Gore Acquires Pipeline Medical Technologies, Inc.

Acquisition of transcatheter mitral chordal repair technology builds on Gore’s structural heart capabilities

FLAGSTAFF, Ariz. (September 6, 2018) – W. L. Gore & Associates, Inc. (Gore) a global leader in providing solutions for cardiovascular disease, announced the acquisition of Pipeline Medical Technologies, Inc., a privately held medical technology company focused on advancing chordal repair for degenerative mitral regurgitation (DMR) via a transcatheter procedure.

“The addition of Pipeline's investigational technology and talented associates bolsters our continued ambition to improve patients’ lives by offering physicians innovative treatment solutions across the cardiac space,” said David Abeyta, Leader of Gore Medical Products Division. “Pipeline’s cutting-edge repair procedure, for patients with mitral valve disease, has the potential to expand Gore’s growing portfolio of treatments for structural heart disease, and it echoes our commitment to innovation across cardiac therapies.”

The Pipeline device is designed to replicate the outcomes of a highly effective surgical procedure via a catheter, avoiding the trauma and many of the risks associated with open heart surgery. “An entirely catheter-based, transfemoral and transseptal chordal repair will be an important tool for minimally invasive treatment of mitral regurgitation,” commented Paul Sorajja, MD, Director, Center for Valve and Structural Heart Disease, Minneapolis Heart Institute at Abbott Northwestern Hospital.

“We see an array of synergies working with Gore. The company is well recognized for its advanced material capabilities. Its long history of designing solutions for DMR treatment challenges already includes the GORE-TEX® Suture for Chordae Tendineae, used in surgical chordal repairs and we are excited to collaborate on future innovations in transcatheter mitral chordal repair,” said Pipeline founder Steven Bolling, MD, a leading mitral valve surgeon. “Together we aspire to significantly advance DMR patient outcomes and improve recovery speed.”

The company will retain the Pipeline name and operate independently of Gore as a wholly owned subsidiary. Pipeline’s device is currently in development and not available for commercial use.

* For complete indications and other important safety information for Gore commercial products referenced herein, refer to the applicable Instructions for Use (IFU).

MEDICAL PRODUCTS DIVISION

Gore Medical Products Division engineers devices that treat a range of cardiovascular and other health conditions. With more than 40 million medical devices implanted over the course of more than 40 years, Gore builds on its legacy of improving patient outcomes through research, education and quality initiatives. Product performance, ease of use, and quality of service provide sustainable cost savings for physicians, hospitals and insurers. Gore is joined in service with clinicians, and through this collaboration we are improving lives. www.goremedical.com

ABOUT W. L. GORE & ASSOCIATES

W. L. Gore & Associates is a global materials science company dedicated to transforming industries and improving lives. Founded in 1958, Gore has built a reputation for solving complex technical challenges in the most demanding environments — from revolutionizing the outerwear industry with GORE-TEX® fabric to creating medical devices that improve and save lives to enabling new levels of performance in the aerospace, pharmaceutical and mobile electronics markets, among other industries. The company is also known for its strong, team-oriented culture and continued recognition from the Great Place to Work® Institute. Headquartered in Newark, Del., Gore employs approximately 10,000 Associates and generates annual revenues that exceed $3.5 billion. www.gore.com